secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0000950170-23-033594
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio shareholders elect three Class II directors, ratify Deloitte as auditor
--------------------------------------------------------------------------------

- Abraham Bassan, Matthew Porteus, and Jo Viney elected with >35.8M votes each; 5.6M broker non-votes.
- Deloitte & Touche ratified as FY2023 auditor: 44,039,995 for, 11,869 against, 55,188 abstentions.
- Total shares entitled to vote: 58,102,949; shares present/proxy: 44,107,052.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023033594/0000950170-23-033594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000095017023033594/grph-20230719.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-033594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer